1. Yüceer S, Demir SG. Yoğun bakım ünitesinde nozokomiyal enfeksiyonların önlenmesi ve hemşirelik uygulamaları. Dicle Tıp Dergisi. 2009; 36: 226-232.
2. Platt R, Goldman RA, Hopkıns CC. Epidemiology of nosocomial infections. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. İnfectious Diseases. Philadelphia: WB Sounders Company, 96-106, 1992.
3. Larsen AR. Nosocomial infections. In: Hoeprich PD, Jordan MC, eds. Infectious Disease 4th. Ed Phledelpiha: J.B.Lippincott Company, 35-40, 1989.
4. Alberti C, Brun-Buisson C, Burchardi H et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study, Intensive Care Med. 2002; 28: 108-121.
5. Karaman R. Yoğun bakım infeksiyonlarında hemşirenin rolü. Yoğun Bakım Dergisi. 2002; 2: 5-8.
6. Mülazımoğlu L. Yoğun bakımda çoklu dirençli mikroorganizma sorunu. Yoğun Bakım Dergisi. 2006; 6: 27-29.
7. Çaylan R. Enfeksiyon kontrolüne yönelik genel önlemler. Yoğun Bakım Dergisi. 2006; 6: 8-10.
8. Aktaş F. Gram-negatif bakterilerin hastane infeksiyonlarındaki rolü ve epidemiyolojisi. In Ulusoy S, Leblebicioğlu H, Arman D (eds): Önemli ve sorunlu Gram Negatif Bakteri İnfeksiyonları. Bilimsel Tıp Yayınevi, Ankara, 183–206, 2004. 9. Özmen E, Geyik MF, Uluğ M, Çelen MK, Hoşoğlu S, Ayaz C. Yatan Hastalardan İzole Edilen Gram Negatif Bakteriler ve Antibiyotik Dirençlerinin Değerlendirilmesi. Düzce Tıp Dergisi. 2010; 12(3): 32-39.
10. Çetin ES, Kaya S, Tetik T, Cicioğlu Arıdoğan B. Klinik Örneklerden İzole Edilen Acinetobacter baumannii Suşlarının Örneklere Göre Dağılımı ve Antibiyotik duyarlılıkları. Ankem Dergisi. 2006; 20(4): 202-205.
11. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-
resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004; 48(3): 753- 757.
12. Yurtsever SG, Altıner N, El S, Çetin FL, Pişmişoğlu E, Uzun S. Hastane infeksiyonu etkeni olarak çeşitli klinik örneklerden izole edilen Acinetobacter baumannii izolatlarının antibiyotik duyarlılıkları. Ankem Dergisi. 2008; 22(3): 148- 152.
13. Camkıran A, Kundakcı A, Araz C ve ark. Cerrahi Yoğun Bakım Ünitesinde Çok İlaca Dirençli Acinetobacter baumannii Enfeksiyonunun Ön Belirleyicileri: Retrospektif Bir Analiz. Türk Yoğun Bakım Derneği Dergisi / Journal of the Turkish Society of Intensive Care. 2011; 9: 53-58.
14. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21(3): 538-582.
15. Gordon NC, Wareham DW. Multidrugresistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010; 35: 219-226. 16. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of Clinical Microbiology. Başustaoğlu A (Çeviren) 9.baskı, Nobel Yayınevi, Ankara. 770-794, 2009.
17. Çiftçi İH, Aşık G. Acinetobacter baumannii’nin antibiyotik direnç mekanizmaları. Ankem Derg. 2011; 25(3): 196-207.
18. Yıldırım İH. Sefaperazon-Sulbaktam, İmipenem ve Sefepimin Antibiyoterapi Etkinliklerinin Çoğul Dirençli ve Duyarlı Acinetobacter baumannii ile Oluşturulan Deneysel İkili Apse Modelinde Karşılaştırılması. Uzmanlık Tezi. Trakya Üniversitesi Tıp Fakültesi. Edirne 2006. s.5.
19. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect. 2009; 73(4): 355-363.
20. Bergogne-Berezin E, Towner KJ. Acinetobacter spp as nosocomial pathogens: Microbiological, clinical and epidemiological features. Clin Microbiol Rev. 1996; 9: 148- 165.
21. Hanlon GW. The emergence of multidrug resistant Acinetobacter species: a major concern in the hospital setting. Lett Appl Microbiol. 2005; 41(5): 375-378.
22. Bahar İH, Esen N. Acinetobacter türleri ve diğer gram negatif nonfermentatif basiller. İçinde: Topçu AW, Söyletir G, Doğanay M (Editörler). Enfeksiyon Hastalıkları ve Mikrobiyolojisi. Nobel Tıp Kitabevi, İstanbul. 2195-2201, 2008. 23. Bartual SG, Seifert H, Hippler C, Luzon MA, Wisplinghoff H, Rodriguez-Valera F. Development of a multilocus seguence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005; 43: 4382-4390. 24. Towner KJ. Acinetobacter. In: Collier L, Balows A, Susman M, (eds.) Topley&Wilson’s Microbiology and Microbial Infections. 9 th ed. London. 1229- 1239, 1998.
25. Ersavaş H. Çeşitli Antibiyotik Kombinasyonlarının Çoğul İlaca Dirençli Acinetobacter baumannii Suşlarına İn Vitro Etkileri. Uzmanlık Tezi. Süleyman Demirel Üniversitesi Tıp Fakültesi. Isparta 2009. s.2
26. Speller DCE, Humphreys H. Hospital-acquired infection. In: Collier L, Balows A, Sussman M (Eds.). Topley&Wilson’s Microbiology and Microbial Infections. 9th ed. London: Arnold;187–229, 1998.
27. Allen DM, Hartman BJ. Acinetobacter species. In: Mandel GL, Bennet JE, Dolin R, ed(s). Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. 5th ed. 2339- 2344, 2000.
28. Jawad A, Snelling AM, Heritage J, Hawkey PM. Exceptional Desiccation Tolerance of Acinetobacter Radioresistens. Journal of Hospital Infection. 1998; 39(3): 235-240.
29. Catalano M, Quelle LS, Jeric PE, Di Martino A, Maimone SM. Survival of Acinetobacter baumannii on Bed Rails During an Outbreak and During Sporadic Cases. Journal of Hospital Infection. 1999; 42(1): 27-35.
30. Ayan M, Durmaz R, Aktas E, Durmaz B. Bacteriological, clinical, and epidemiological characteristics of hospital acquired Acinetobacter baumannii infection in a teaching hospital. J Hosp Infect. 2003; 54: 39–45.
31. Beck-Sague CM, Jarvis WR, Brook JH et al. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. Am J Epidemiol. 1990; 132(4): 723-733.
32. Tilley PA, Roberts FJ. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis. 1994; 18(6): 896-900.
33. Zeana C, Larson E, Sahni J, Bayuga SJ, Wu F, Della-Latta P. The epidemiology of multidrug-resistant Acinetobacter baumannii: does the community represent a reservoir? Infect Control Hosp Epidemiol. 2003; 24(4): 275-279.
34. Coelho J, Woodford N, Turton J, Livermore DM. Multiresistant acinetobacter in the UK: how big a threat? J Hosp Infect. 2004; 58(3): 167-169.
35. Özdemir D. Asinetobakter Enfeksiyonları: Direnç Epidemiyoloji. 3. Türkiye EKMUD Bilimsel Platformu kitabı, s.249-255. 3. Türkiye EKMUD Bilimsel Platformu, İstanbul, 1-5 Mart 2011.
36. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. Community- acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol. 2002; 40(2): 685-686.
37. D’Agata EMC, Thayer V, Schaffner W. An outbreak of Acinetobacter baumannii: The importance of cross-transmission. Infect Control Hosp Epidemiol. 2000; 21: 588- 591.
38. Dy ME, Nord JA, LaBombardi VJ, Kislak JW. The emergence of resistant strains of Acinetobacter baumannii: clinical and infection control implications. Infect Control Hosp Epidemiol. 1999; 20: 565- 567.
39. Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and Other Nonfermentative Gram- Negative Rods. In: Murray PR, Baron EJ, Pfaller MA, Landry ML, Jorgensen JH. (Eds.). Manuel of Clinical Microbiology 9 th ed. Washington ASM Pres, 770- 802, 2007.
40. McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial Infections Surveillance System. Clin Infect Dis. 1999; 29(5): 1133-1137.
41. Can F, Kurt Azap Ö, Demirbilek M, Karabay G, Timurkaynak F, Arslan H. Kan kültürlerinden izole edilen Acinetobacter baumannii suşlarında biyofilm oluşumu. İnfeksiyon Dergisi (Turkish Journal of Infection). 2006; 20 (3): 159-163.
42. Obana Y. Pathogenic significance of Acinetobacter calcoaceticus: analysis of experimental infection in mice. Microbiol Immunol. 1986; 30(7): 645-657.
43. Vahaboglu H, Coskunkan F, Tansel O et al. Clinical importance of extended- spectrum beta-lactamase (PER–1-type) producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J Med Microbiol. 2001; 50: 642–645.
44. Towner K. The Genus Acinetobacter. Prokaryotes. 2006; 6: 746-758.
45. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn Jr.WC. Color atlas and textbook of diagnostic microbiology, 5. Baski kitabinda. Philadelphia: Lippincott; 253-320, 1997.
46. Gaynes R, Edwards JR, Overview of Nosocomial Infections Caused by Gram- Negative Bacilli. Clinical Infectious Diseases. 2005; 41: 848-854.
47. Munoz-Price LS, Weinstein RA. Acinetobacter Infection. N Engl J Med. 2008; 358 (12): 1271-1281.
48. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore). 1995; 74: 340-349.
49. Cisneros JM, Reyes MJ, Pachon J et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis. 1996; 22: 1026-1032.
50. Ferrara AM. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia. International Journal of Antimicrobial Agents. 2006; 27: 183-195.
51. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin İnfect Dis. 2001 May 15;32 Suppl 2:S104-13.
52. Park DR. The Microbiology of Ventilator-Associated Pneumonia. Respiratory Care. 2005; 50(6): 742-765.
53. Crnich CJ, Safdar N, Maki DG. The Role of the Intensive Care Unit Environment in the Pathogenesis and Prevention of Ventilator-Associated Pneumonia. Respiratory Care. 2005; 50(6); 813-838.
54. Leblebicioğlu H, Rosenthal VD, Arıkan A et al. Device-associated hospital- acquired infection rates in Turkish intensive care units. Findings of the International
Nosocomial Infection Control Consortium (INICC), Journal of Hospital Infection. 2007; 65: 251-257.
55. Saltoğlu N. Acinetobacter baumannii İnfeksiyonları ve Tedavisi. 13. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları (KLİMİK) kongre kitabı. s.204-207. 13. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi, Antalya, 14-18 Mart 2007.
56. Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Lippincott Williams & Wilkins. 2003; 9: 413- 423.
57. Özyurt M, Albay A, Kısa Ö, Başustaoğlu A, Gün H. Klinik örneklerden izole edilen Acinetobacter baumannii izolatlarının çeşitli antibiyotiklere duyarlılıkları, İnfeksiyon Derg. 1998; 12(3): 365-369.
58. Yaylı G, Aksoy S. Hastane infeksiyonlarından izole edilen Acinetobacter suşlarının antibiyotiklere duyarlılıkları, Türk Mikrobiyol Cem Derg. 2003; 33(1): 61- 63.
59. Çelik İH, Demirel G, Aksoy HT ve ark. Acinetobacter baumannii: Yenidoğanlarda Çoklu İlaç Direncine Sahip Önemli Bir Patojen. Mikrobiyol Bul. 2011; 45(4): 716-722.
60. Aygün G, Öztürk G. Acinetobacter cinsi bakteriler ve enfeksiyonları. Vahaboğlu H (eds). Yeni ve Yeniden Gündeme Gelen infeksiyonlar. 2004; 21-25.
61. Chen HP, Lai CH, Chan YJ et al. Clinical significance of Acinetobacter species isolated from cerebrospinal fluid. Scandinavian Journal of Infectious Diseases. 2005; 37: 669-675.
62. Gospodarek E, Krasnicki K, Ziolkowski G, Kasprzak H, Beuth W. Cerebrospinal meningitis with the presence of Acinetobacter spp. Med Sci Monit. 2000; 6(1): 50- 54.
63. Katragkou A, Roilides E. Successful Treatment of Multidrug-Resistant Acinetobacter baumannii Central Nervous System Infections with Colistin. Journal Of Clinical Microbiology. 2005; 4916-4917.
64. Gleeson T, Petersen K, Mascola J. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. Journal of Antimicrobial Chemotherapy. 2005; 602-603.
65. Trottier V, Segura PG, Namias N, King D, Pizano LR, Schulman CI. Outcomes of Acinetobacter baumannii infection in critically ill burned patients. J. Burn Care Res. 2007; 28(2): 248-254.
66. Gündeş S, Vahaboğlu H. Acinetobacter türleri ve Acinetobacter ile gelişen enfeksiyonlar. Enfeksiyon Hastalıkları Serisi. 2003; 6: 147-156.
67. Menon T, Shanmugasundaram S, Nandhakumar B, Nalina K, Balasubramaniam. Infective endocarditis due to Acinetobacter baumannii complex a case report. Indian J. Pathol. Microbiol. 2006; 49(4): 576-578.
68. Corrigan KM, Harmis NY, Willcox MD. Association of Acinetobacter species with contact lens-induced adverse responses. Cornea. 2001; 20(5): 463-466.
69. Lye WC, Lee EJ, Ang KK. Acinetobacter peritonitis in patients on CAPD: characteristics and outcome. Adv Perit Dial. 1991; 7: 176-179.
70. Ardıç N, Özyurt M, İlga U, Erdemoğlu A, Haznedaroğlu T. Yatan hastalardan izole edilen Pseudomonas aeruginosa ve Acinetobacter suşlarının karbapenemlere ve bazı antibiyotiklere duyarlılıkları. Ankem Derg. 2004; 18: 145-148.
71. Erben N, Kiremitçi A, Özgüneş İ ve ark. Klinik örneklerden izole edilen Acinetobacter türlerinde genişletilmiş spektrumlu beta-laktamaz ve indüklenebilir beta-laktamaz sıklığının ve antimikrobiyal duyarlılığın değerlendirmesi. Osmangazi Tıp Derg. 2006; 28(3): 135-146.
72. Gençer S, Benzonana N, Özer S, Kuzu İ, Özyurt Y. Cerrahi Yoğun Bakım Ünitesinden izole edilen bakteriler ve antibiyotik duyarlılıkları, Yoğun Bakım Derg. 2001; 1(2): 131-137.
73. Longo B, Pantosti A, Luzzi I. Molecular findings and antibiotic-resistance in an outbreak of Acinetobacter baumannii in an intensive care unit. Ann Ist Super Sanità. 2007; 43(1): 83-88.
74. Katragkou A, Kotsiou M, Antachopoulos C et al. Acquisition of imipenem- resistant Acinetobacter baumannii in a pediatric intensive care unit: a case-control study. Intensive Care Med. 2006; 32(9): 1384-1391.
75. Chang PY, Hsueh PR, Wu PS et al. Multidrug-resistant Acinetobacter baumannii isolates in pediatric patients of a university hospital in Taiwan. J Microbiol Immunol Infect. 2007; 40: 406-410.
76. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006; 42: 692-699. 77. Gómez J, Simarro E, Banos V. Six-Year Prospective Study of Risk and Prognostic Factors in Patients with Nosocomial Sepsis Caused by Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 1999; 18 :358-361.
78. Kunz AN, Brook I. Emerging resistant Gram-negative aerobic bacilli in hospital- acquired infections. Chemotherapy. 2010; 56(6): 492-500.
79. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents. 2010; 3653: 8-14.
80. Gür D, Korten V, Ünal S, Deshpande LM, Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol. 2008; 57: 1529-1532.
81. Ko KS, Suh JY, Kwon KT et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother. 2007; 60(5): 1163-1167.
82. Yazıcı S. Acinetobacter İnfeksiyonları. Ed: Yalçın AN, Erbay RH. Yoğun Bakım Ünitesinde İnfeksiyonlar kitabı, İstanbul. 129-135, 2009.
83. Aşçı Toraman Z, Yakupoğulları Y, Kizirgil A. Pseudomonas ve Acinetobacter suşlarında metallo beta-laktamaz araştırılması. İnfeksiyon Dergisi (Turkish Journal of Infection). 2005; 19 (1): 101-105.
84. del Mar Tomás M, Beceiro A, Pérez A et al. Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005; 49(12): 5172-5175.
85. Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol. 2002; 40(12): 4776-4778.
86. Siroy A, Molle V, Lemaître-Guillier C et al. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob Agents Chemother. 2005; 49(12): 4876-4883.
87. Gehrlein M, Leying H, Cullmann W, Wendt S, Opferkuch W. Imipenem resistance in Acinetobacter baumanii is due to altered penicillin-binding proteins. Chemotherapy. 1991; 37(6): 405-412.
88. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents. 2010; 35(3): 219- 226.
89. Shi WF, Jiang JP, Mi ZH. Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J. 2005; 118(2): 141-145.
90. Higgins PG, Coleman K, Amyes SG. Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro. J Antimicrob Chemother. 2000; 45: 71-77.
91. Wisplinghoff H, Decker M, Haefs C, Krut O, Plum G, Seifert H. Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy. 2003; 51: 177-180.
92. Wareham DW, Bean DJ, Khanna P et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008; 27: 607–612.
93. Munoz-Price L, Weinstein R. Acinetobacter Infection. N Engl J Med. 2008; 358: 1271-1281.
94. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008; 46(8): 1254-1263.
95. Mushtaq S, Ge Y, Livermore DM. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother. 2004; 48(4): 1313-1319.
96. Eraksoy H, Basustaoglu A, Korten V et al. Susceptibility of bacterial isolates from Turkey-a report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC). Program. J Chemother. 2007; 19(6): 650-657.
97. Gür D, Gülay Z, Hitit 2 Surveyansı Çalışma Grubu. Gram negatif hastane izolatlarında antibiyotiklere direnç-Hitit-2 surveyans çalışmasının sonuçları (2007) [Özet]. In: Saltoğlu N, Sakarya S, eds. 14. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Kongresi Kongre Kitabı. İstanbul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği & Türk Mikrobiyoloji Cemiyeti, 2009: 196. Antalya, 25-29 Mart 2009
98. Çaylan R, Aydın K, Köksal İ, Volkan S. Acinetobacter suşlarının izole edildiği hastalardaki hazırlayıcı faktörler ve suşların antibiyotiklere duyarlılıkları. ANKEM Derg. 1998; 12(1): 63-69.
99. Özdemir M, Eryaman İ, Gündem NS, Baykan M, Baysal B. Hastane infeksiyonu etkeni Acinetobacter suşlarının çeşitli antibiyotiklere duyarlılıklarının araştırılması. ANKEM Derg. 2009; 23(3): 127-132.
100. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis. 2005; 37: 195-199.
101. Punpanich W, Munsrichoom A, Srisarang S, Treeratweeraphong V. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii. J Med Assoc Thai. 2011; 94(3): 95-100.
102. Akova M. Sulbaktam-Sefoperazon: In Vitro Çalışmalar ve Klinik Kullanımında Yeni Veriler. Flora 2006; 11(Ek 2)
103. Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008; 61: 417–420.
104. Peleg AY, Potoski BA, Rea R et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007; 59(1): 128-131.
105. Kuşçu F, Öztürk DB, Tütüncü EE ve ark. Çoğul Antibiyotik Dirençli Acinetobacter baumannii İzolatlarında Tigesiklin Duyarlılık Oranlarının E-Test Yöntemiyle Araştırılması. Klimik Dergisi. 2009; 22(2): 48-51.
106. Yemişen M, Özaras R. Kolistin. Flora derg. 2011; 16(3): 15-26.
107. Rosenthal VD, Guzmán S, Crnich C. Device-Associated Nosocomial Infection Rates In Intensive Care Units Of Argentina. Infect Control Hosp Epidemiol. 2004; 25: 251-255.
108. Meriç M, Wilke A, Çaglayan Ç, Toker K. intensive care unit-acquired infections: incidence, risk factors and associated mortality in a Turkish University Hospital. Jpn. J. Infect. Dis. 2005; 58: 297-302.
109. Prashanth K, Badrinath S. Nosocomial infections due to Acinetobacter species: clinical findings, risk and prognostic factors. Indian Journal of Medical Microbiology. (2006; 24(1): 39-44.
110. Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications, Clin Microbiol Infect. 2007; 13: 117–119.
111. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001; 134: 298-314.
112. Gür D. Hastane infeksiyonları ve antimikrobiyal ilaçlara çoğul dirençli gram- negatif bakteriler. Hastane İnfeksiyonları Dergisi. 2000; 4: 218-221.
113. Mulin B, Talon D, Viel JF et al. Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 1995; 14: 569-576.
114. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010; 25(6): 343-348.
115. Ye JJ, Huang CT, Shie SS et al. (2010) Multidrug Resistant Acinetobacter baumannii: Risk Factors for Appearance of Imipenem Resistant Strains on Patients Formerly with Susceptible Strains. PLoS ONE 5(4): e9947. doi:10.1371/journal.pone.0009947
116. Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F et al. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect. 2005; 11: 874–879.
117. Kim YJ, Kim SI, Kim YR et al. Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol. Infect. 2012; 140: 137-145.
118. Park YS, Lee H, Lee KS et al. Extensively drug-resistant Acinetobacter baumannii: risk factors for acquisition and prevalent OXA-type carbapenemases-a multicentre study. International Journal of Antimicrobial Agents. 2010; 36: 430-435. 119. Sheng WH, Liao CH, Lauderdale TL et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. International Journal of Infectious Diseases. 2010; 14: 764-769.
120. Beavers SF, Blossom DB, Wiemken TL et al. Comparison of Risk Factors for Recovery of Acinetobacter baumannii During Outbreaks at Two Kentucky Hospitals, 2006. Public Health Reports. 2009; 124: 868-874.
121. Chang HC, Chen YC, Lin MC et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator-associated pneumonia. Journal of the Formosan Medical Association. 2011; 110: 564-571.
122. Deris ZZ, Harun A, Omar M, Johari R. The prevalence and risk factors of nosocomial Acinetobacter blood stream infections in tertiary teaching hospital in north-eastern Malaysia. Tropical Biomedicine. 2009; 26(2): 123-129.
123. Medina J, Formento C, Pontet J et al. Prospective study of risk factors for ventilator-associated pneumonia caused by Acinetobacter species. Journal of Critical Care. 2007; 22(1): 18-26.
124. Surasarang K, Narksawat K, Danchaivijitr S et al. Risk factors for multi-drug resistant Acinetobacter baumannii nosocomial infection. J Med Assoc Thai. 2007; 90(8): 1633-1639.
125. Lee SO, Kim NJ, Choi SH et al. Risk Factors for Acquisition of Imipenem- Resistant Acinetobacter baumannii: a Case-Control Study. Antimicrobial Agents and Chemotherapy. 2004; 224-228.
126. Baran G, Erbay A, Bodur H et al. Risk factors for nosocomial imipenem- resistant Acinetobacter baumannii infections. International Journal of Infectious Diseases. 2008; 12: 16-21.
127. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infectious Diseases. 2010; 10: 196.
128. Kütük E. Yoğun Bakım Ünitesinde A. baumannii Enfeksiyonu, Risk Faktörleri ve Antibiyotik Direnç Durumları. Uzmanlık Tezi. Dicle Üniversitesi Tıp Fakültesi Diyarbakır 2011 s:33
129. Alp E, Yerener M, Kocagoz S et al. The risk factors and spread of multidrug- resistant Acinetobacter baumannii in intubated patients in a medical intensive care unit. Turk J Med Sci. 2009; 39 (5): 761-769.
130. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 2001; 32: 1055-1061.
131. Aygün G. Yoğun bakım birimi infeksiyonlarında çevre şartlarının önemi. Klimik Dergisi. 2003; 16(3): 106-107.